Evidence map›Paper›PMID 38543161›Full record

ArticlePharmaceuticals (Basel, Switzerland)2024

Small-Angle X-ray Scattering (SAXS) Used for the Identification of Nicomorphine Polymorphic Changes at the Early Stage to Avoid Varied Stability and Possible Side Effects.

Nermina Malanovic, Giovanni Birarda, Simone Eder, Heidrun Gruber-Woelfler, Franz Reiter, Krunoslav Juraic, Aden Hodzic

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 6 institutions in 3 countries.

Nermina MalanovicInstitute of Molecular Biosciences, University of Graz, 8010 Graz, Austria.ORCID 0000-0002-2903-9369
Giovanni BirardaElettra Synchrotron, Basovizza, 34149 Trieste, Italy.ORCID 0000-0003-2418-058X
Simone EderInstitute of Pharmaceutical Sciences, University of Graz, 8010 Graz, Austria.
Heidrun Gruber-WoelflerResearch Center Pharmaceutical Engineering GmbH, 8010 Graz, Austria.ORCID 0000-0002-6917-4442
Franz ReiterG.L. Pharma GmbH, 8502 Lannach, Austria.
Krunoslav JuraicRudjer Boskovic Institute, 10000 Zagreb, Croatia.ORCID 0000-0001-9653-7723
Aden HodzicResearch Center Pharmaceutical Engineering GmbH, 8010 Graz, Austria.
University of Graz · ATAREA Science Park · ITElettra-Sincrotrone Trieste S.C.p.A. · ITGerot Lannach (Austria) · ATGraz University of Technology · ATRuđer Bošković Institute · HR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this paper, we present the identification of polymorphisms at an early stage, identified by applying non-standard methods such as SAXS. We provide an analytical approach to polymorphism in the quality/purity of an active pharmaceutical ingredient (API), supplied to a generic company by two different suppliers (i.e., manufacturers). Changes in thermodynamic polymorphism firstly become visible in traces in the larger crystal lattices, which are visible on the SAXS spectrum only using the logarithmic scale, as shown in the result figures. Hence, we are here on the trail of the beginning of a new polymorph in nicomorphine, whose crystal waviness at the early stage is visible only in the additional symmetrical peaks identified and calculated using SAXS, while the chemical analyses excluded all kinds of chemical impurities. The chemical and structural properties were studied using the following techniques: SAXS, WAXS, DSC, dissolution, Raman spectroscopy, and FTIR. Only the SAXS technique could identify crucial differences and calculate the additional signals related to giant crystals, whilst a standard method such as WAXS showed none, and nor did the chemical analyses, such as Raman spectroscopy and FT-IR. This means that due to water in crystallization (known in nicomorphine) or thermodynamic waviness, the formation of the new polymorph starts first in traces, which become visible at larger distances from the crystal lattice, detectible only in the SAXS range. This is a very important premise and hypothesis for further research, and we believe that this work lays a new stone in understanding the origin of new unknown polymorphs and their mixtures. Therefore, the aim of this work is to show that the use of non-standard methods (i.e., SAXS) can be of great benefit to API analysis and the identification of polymorphic changes in the early phase, which can cause varied stability, solubility and bioavailability and thus different therapeutic effects or side effects.

Indexed as

crystallinitydissolutionDSCFTIRpolymorphismpowderpurityRamansmall-angle X-ray scatteringsolid-state drugs

Identifiers

PMID38543161
PMCPMC10975358
OpenAlexW4392861649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.